Presentation is loading. Please wait.

Presentation is loading. Please wait.

Red Cell Disorders Robert E. Richard, MD, PhD Assistant Professor Division of Hematology University of Washington School of Medicine

Similar presentations


Presentation on theme: "Red Cell Disorders Robert E. Richard, MD, PhD Assistant Professor Division of Hematology University of Washington School of Medicine"— Presentation transcript:

1 Red Cell Disorders Robert E. Richard, MD, PhD Assistant Professor Division of Hematology University of Washington School of Medicine faculty.washington.edu/rrichard

2 Objectives Review red blood cell disorders for which transfusions are therapeutic. Discuss controversial areas of transfusion therapy in red blood cell disorders. Understand the risks related to long term transfusion therapy (non-infectious).

3 Anemia is operationally defined as a reduction in one or more of the major RBC measurements: hemoglobin concentration, hematocrit, or RBC count Keep in mind these are all concentration measures Definition:

4 …most accurately measured by obtaining a RBC mass via isotopic dilution methods! (Please don’t order that test!)

5 Review red blood cell disorders Marrow Production

6 Two main approaches that are not mutually exclusive: Biologic or kinetic approach. 1. Biologic or kinetic approach. Morphology. 2. Morphology.

7 Anemia Production?Survival/Destruction? The key test is the ….. ?

8 The reticulocyte count (kinetic approach) Increased reticulocytes (greater than 2-3% or 100,000/mm 3 total) are seen in blood loss and hemolytic processes, although up to 25% of hemolytic anemias will present with a normal reticulocyte count due to immune destruction of red cell precursors. Retic counts are most helpful if extremely low (<0.1%) or greater than 3% (100,000/mm 3 total).

9 The reticulocyte count To be useful the reticulocyte count must be adjusted for the patient's hematocrit. Also when the hematocrit is lower reticulocytes are released earlier from the marrow so one can adjust for this phenomenon. Thus: Corrected retic. = Patients retic. x (Patients Hct/45) Reticulocyte index (RPI) = corrected retic. count/Maturation time (Maturation time = 1 for Hct=45%, 1.5 for 35%, 2 for 25%, and 2.5 for 15%.) Absolute reticulocyte count = retic x RBC number.

10 Causes of Anemia (kinetic approach) Decreased erythrocyte production Decreased erythropoietin production Inadequate marrow response to erythropoietin Erythrocyte loss Hemorrhage Hemolysis

11 First, measure the size of the RBCs: Use of volume-sensitive automated blood cell counters, such as the Coulter counter. The red cells pass through a small aperture and generate a signal directly proportional to their volume. Other automated counters measure red blood cell volume by means of techniques that measure refracted, diffracted, or scattered light By calculation from an independently-measured red blood cell count and hematocrit: MCV (femtoliters) = 10 x HCT(percent) ÷ RBC (millions/µL) Morphological Approach (big versus little)

12 Underproduction (morphological approach) MCV>115 B12, Folate Drugs that impair DNA synthesis (AZT, chemo) MDS MCV Ditto endocrinopathy (hypothyroidism) Epo reticulocytosis

13 Underproduction Normocytic Anemia of chronic disease Mixed deficiencies Renal failure Microcytic Iron deficiency Thal. trait Anemia of chronic disease (30-40%) sideroblastic anemias

14 Review red blood cell disorders Marrow production Thalassemias Myelodysplasia Myelophthisic Aplastic anemia Nutritional deficiencies Red cell destruction Hemoglobinopathies Enzymopathies Membrane disorders Autoimmune

15

16 Acquired –Immunological –Toxins – Benzene –Drugs – methotrexate, chloramphenicol –Viruses – EBV, hepatitis Hereditary –Fanconi, –Diamond-Shwachman Review red blood cell disorders Marrow Production - Aplastic Anemia

17 All lineages affected. Most patients require red cell transfusions. Transplant when possible. Transfusions should be used selectively to avoid sensitization (no family donors!). Review red blood cell disorders Marrow Production - Aplastic Anemia

18 Preleukemia, most commonly in the elderly. Supportive care that involves transfusion therapy is an option. Poor response to growth factors Review red blood cell disorders Marrow Production - Myelodysplasia

19 Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol. 1994;68: (early review)

20 Anemia associated with marrow infiltration “teardrops” Cancer, infections Treatment is aimed at the underlying disease Supportive transfusions as needed. Review red blood cell disorders Marrow Production - Myelophthisic

21 Elevated reticulocyte count Mechanical Autoimmune Drug Congenital Review red blood cell disorders Red cell destruction

22 Hemolytic Anemias Hemolytic anemias are either acquired or congenital. The laboratory signs of hemolytic anemias include: 1. Increased LDH (LDH1) - sensitive but not specific. 2. Increased indirect bilirubin - sensitive but not specific. 3. Increased reticulocyte count - specific but not sensitive 4. Decreased haptoglobin - specific but not sensitive. 5. Urine hemosiderin - specific but not sensitive. The indirect bilirubin is proportional to the hematocrit, so with a hematocrit of 45% the upper limit of normal is 1.00 mg/dl and with a hematocrit of 22.5% the upper limit of normal for the indirect bilirubin is 0.5mg/dl. Since tests for hemolysis suffer from a lack of sensitivity and specificity, one needs a high index of suspicion for this type of anemia.

23 Hereditary spherocytosis Hereditary elliptocytosis Hereditary pyropoikilocytosis Southeast Asian ovalocytosis Review red blood cell disorders Red cell destruction – membrane disorders

24

25 G6PD deficiency Pyruvate kinase deficiency Other very rare deficiencies Review red blood cell disorders Red cell destruction – enzymopathies

26 Sickle Cell Anemia Single base pair mutation results in a single amino acid change. Under low oxygen, Hgb becomes insoluble forming long polymers This leads to membrane changes (“sickling”) and vasoocclusion

27

28 Red Blood Cells from Sickle Cell Anemia OXY-STATEDEOXY-STATE Deoxygenation of SS erythrocytes leads to intracellular hemoglobin polymerization, loss of deformability and changes in cell morphology.

29 Deoxyhemoglobin S Polymer Structure A) Deoxyhemoglobin S 14-stranded polymer (electron micrograph) D) Charge and size prevent 6  Glu from binding. C) Hydrophobic pocket for 6  Val B) Paired strands of deoxyhemoglobin S (crystal structure) Dykes, Nature 1978; JMB 1979 Crepeau, PNAS 1981 Wishner, JMB 1975

30 Transfusion in Sickle Cell (Controversy!) Used correctly, transfusion can prevent organ damage and save the lives of sickle cell disease patients. Used unwisely, transfusion therapy can result in serious complications. m

31 Simple transfusion – give blood Partial exchange transfusion - remove blood and give blood Erythrocytapheresis – use apheresis to maximize blood exchange When to use each method? Transfusion in Sickle Cell (Controversy!)

32 In severely anemic patients, simple transfusions should be used. Common causes of acute anemia: acute splenic sequestration transient red cell aplasia Hyperhemolysis (infection, acute chest syndrome, malaria). If the patient is stable and the reticulocyte count high, transfusions can (and should) be deferred. Transfusion in Sickle Cell

33 In general, patients should be transfused if there is sufficient physiological derangement to result in heart failure, dyspnea, hypotension, or marked fatigue. Tends to occur during an acute illness or when hemoglobin falls under 5 g/dL. Transfusion in Sickle Cell

34 Except in severe anemia, exchange transfusion offers many benefits and is our first choice Phenotypically matched, leukodepleted packed cells are the blood product of choice. A posttransfusion hematocrit of 36 percent or less is recommended. Avoid hyperviscosity, which is dangerous to sickle cell patients. Transfusion in Sickle Cell (exchange transfusion)

35 Exchange transfusion: 1.Bleed one unit (500 ml), infuse 500 ml of saline 2.Bleed a second unit and infuse two units. 3.Repeat. If the patient has a large blood mass, do it again. Transfusion in Sickle Cell (exchange transfusion)

36 A comprehensive transfusion protocol should include accurate records of the patient’s red cell phenotype, alloimmunization history, number of units received, serial Hb S percentages, and results of monitoring for infectious diseases and iron overload. Transfusions are used to raise the oxygen- carrying capacity of blood and decrease the proportion of sickle red cells. Transfusion in Sickle Cell (exchange transfusion)

37 Transfusions usually fall into two categories:  episodic, acute transfusions to stabilize or reverse complications.  long-term, prophylactic transfusions to prevent future complications. Transfusion in Sickle Cell (exchange transfusion)

38 episodic, acute transfusions to stabilize or reverse complications.  Limited studies have shown that aggressive transfusion (get Hgb S < 30%) may help in sudden severe illness.  May be useful before general anesthesia. Vichinsky et al., NEJM 1995 Transfusion in Sickle Cell (exchange transfusion)

39 –Stroke –Chronic debilitating pain –Pulmonary hypertension –Setting of renal failure and heart failure Transfusion in Sickle Cell (chronic transfusion therapy)

40 Controversial uses: –Prior to contast media exposure –Sub-clinical neurological damage –Priapism –Leg Ulcers –Pregnancy Transfusion in Sickle Cell (chronic transfusion therapy)

41 Inappropriate uses of transfusion: –Chronic steady-state anemia –Uncomplicated pain episodes –Infection –Minor surgery –Uncomplicated pregnancies –Aseptoic necrosis Transfusion in Sickle Cell

42 Thalassemias Genetic defect in hemoglobin synthesis –  synthesis of one of the 2 globin chains (  or  ) –Imbalance of globin chain synthesis leads to depression of hemoglobin production and precipitation of excess globin (toxic) –“Ineffective erythropoiesis” –Ranges in severity from asymptomatic to incompatible with life (hydrops fetalis) –Found in people of African, Asian, and Mediterranean heritage

43 Dx: –Smear: microcytic/hypochromic, misshapen RBCs –  -thal will have an abnormal Hgb electrophoresis (  HbA 2,  HbF) –The more severe  -thal syndromes can have HbH inclusions in RBCs –Fe stores are usually elevated Thalassemias

44 The only treatments are stem cell transplant and simple transfusion. Chelation therapy to avoid iron overload has to be started early.

45

46 Iron overload and chelation Can occur in any patient requiring chronic transfusion therapy or in hemochromatosis. Liver biopsy is the most accurate test though MRI is being investigated. Ferritin is a good starting test. 120 cc of red cells/kg of body weight is an approximate point at which to think about iron overload

47 Chelator, deferoxamine –25 mg/kg sq per day over 8 hours. –Supplementation with vitamin C may aid excretion. –Otooxicity, eye toxicity, allergic reactions. –Discontinue during an infection. Oral chelators are in development. Iron overload and chelation

48 Conclusions Transfuse for any severe anemia with physiologic compromise. Decide early whether transfusion will be rare or part of therapy. Avoid long-term complications by working with your blood bank and using chelation theraoy.

49 SELF (9 frozen pints of artists blood, frozen in sculpture) Mark Quinn


Download ppt "Red Cell Disorders Robert E. Richard, MD, PhD Assistant Professor Division of Hematology University of Washington School of Medicine"

Similar presentations


Ads by Google